[Experience in the treatment of autoimmune male infertility in patients with category 4 chronic prostatitis]
Related Experiment Video
Updated: Apr 15, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Abstract:
Administration of longidaza at a dose of 3000 IU intramuscularly twice a week after 1 month of treatment leads to the statistically significant reduction of antisperm antibodies (ASAB) at the surface of sperm cells to 23% (7-48%) for MARIgG and to 14.5% (3-34%) for MARIgA. Maximum reduction of ASAB, however, was observed after third month of treatment, mean MARIgG was 2% (1-26,5%) and MARIgA - 1% (0-11.5%). ASAB level has not reduced less than 50% only in one patient (1.67%). At follow-up three months after the cancellation of Longidaza, only 17 (28.33%) men showed an increase of ASAB IgG and (or) IgA more than 50%. Inthe study group, during the observation, spontaneous pregnancy occurred in 6 (10%) pairs, and IVF was successfully performed in 3 (5%) pairs. Thus, we consider it necessary to appoint Longidaza in patients with category 4 chronic prostatitis and elevated levels of antisperm antibodies on sperm cells, who preparing for assisted reproductive technologies, or preparing for natural pregnancy, as a high-effective pathogenetical agent for the treatment of autoimmune infertility.
Insights
Longidaza significantly reduces antisperm antibodies (ASAB) in men with chronic prostatitis, improving fertility outcomes. Treatment led to high rates of spontaneous and IVF pregnancy, supporting its use in autoimmune infertility.
Area of Science:
- Reproductive Immunology
- Pharmacology
- Urology
Context:
- Elevated antisperm antibodies (ASAB) are a significant factor in male infertility.
- Chronic prostatitis can be associated with increased ASAB levels.
- Autoimmune infertility impacts a considerable number of couples seeking conception.
Purpose:
- To evaluate the efficacy of Longidaza in reducing ASAB levels in patients with chronic prostatitis.
- To assess the impact of Longidaza treatment on spontaneous and assisted reproductive technology (ART) pregnancy rates.
- To determine the long-term effects of Longidaza on ASAB levels post-treatment.
Summary:
- Longidaza administration (3000 IU IM twice weekly) significantly reduced sperm surface MARIgG and MARIgA levels within one month.
- Maximum ASAB reduction was observed after three months of treatment, with sustained low levels post-cessation in most patients.
- Spontaneous pregnancies occurred in 10% of couples, and IVF was successful in 5% during the study period.
Impact:
- Longidaza demonstrates high efficacy as a pathogenetic agent for treating autoimmune infertility in men with chronic prostatitis and elevated ASAB.
- The study supports the use of Longidaza for patients undergoing ART or attempting natural conception.
- This therapeutic approach offers a potential solution for couples facing challenges with immunological infertility.
Related Concept Videos
Infertility in Males
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Spermatogenesis
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Infertility in Females
Endometriosis, a condition characterized by abnormal growth of...

